Maria Borentain

机构：Bayer (United States), Bristol-Myers Squibb (United States)

发表论文 46 篇 · 总被引 1742 次 · h-index 19

代表论文

• Vericiguat in patients with chronic heart failure and reduced ejection fraction (VICTOR): a double-blind, placebo-controlled, randomised, phase 3 trial (2025 · The Lancet · 被引 82)
• In-Hospital Therapy for Heart Failure With Reduced Ejection Fraction in the United States (2020 · JACC Heart Failure · 被引 56)
• Patients Hospitalized for De Novo Versus Worsening Chronic Heart Failure in the United States (2021 · Journal of the American College of Cardiology · 被引 53)
• Finerenone in Patients With a Recent Worsening Heart Failure Event (2024 · Journal of the American College of Cardiology · 被引 46)
• Vericiguat for patients with heart failure and reduced ejection fraction across the risk spectrum: an individual participant data analysis of the VICTORIA and VICTOR trials (2025 · The Lancet · 被引 45)
• Effects of a Novel Nitroxyl Donor in Acute Heart Failure (2020 · JACC Heart Failure · 被引 25)